Nrc Health (NRC) EBITDA (2010 - 2026)

Nrc Health (NRC) has 17 years of EBITDA data on file, last reported at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 35.21% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $19.6 million (down 44.15% YoY), and the FY2025 full-year result was $22.6 million, down 35.81% from the prior year.
• EBITDA advanced to $5.6 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $12.2 million in Q4 2022 to a low of $1.6 million in Q2 2025.
• A 5-year average of $8.8 million and a median of $9.0 million in 2023 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 1.87% in 2025, while the deepest fall reached 82.09% in 2025.
• Tracing NRC's EBITDA over 5 years: stood at $12.2 million in 2022, then fell by 4.35% to $11.7 million in 2023, then declined by 18.11% to $9.6 million in 2024, then sank by 51.3% to $4.7 million in 2025, then rose by 19.28% to $5.6 million in 2026.
• Business Quant data shows NRC's EBITDA at $5.6 million in Q1 2026, $4.7 million in Q4 2025, and $7.7 million in Q3 2025.